ArticleThe Journal of clinical endocrinology and metabolism2026
Increased MAP-1 and lectin complement activation capacity in Klinefelter syndrome.
Article in The Journal of clinical endocrinology and metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
contextKlinefelter syndrome (KS) is a congenital condition linked to immune dysregulation and metabolic dysfunction with an increased risk of autoimmune, metabolic, and cardiovascular diseases.
objectiveWe examined complement activation through the lectin pathway in men with KS and its relationships with hypogonadism, body composition, and fibrinolytic function.
methodsWe conducted a cross-sectional study comparing men with KS with age-matched controls. We measured lectin pathway complement activation capacity, individual lectin complement factors including the lectin pathway regulator MAP-1, and the main complement split product, C3dg, using ELISAs. Body composition was assessed by dual-energy X-ray absorptiometry, and fibrin clot lysis was analyzed via turbidometry. Additionally, we analyzed skeletal muscle mRNA expression of the MASP1 gene splice variant MASP1-201, which encodes MAP-1.
resultsLectin pathway activation capacity was higher in 45 men with KS compared to 45 male controls (mean ± SD, 106.2 ± 51.6% vs 64.0 ± 30.1%, P < .0001). Serum MAP-1 levels were also elevated in KS patients. MASP1-201 expression was increased in KS. Serum C3dg levels were not different between KS and controls. The lectin pathway activation capacity was not strongly linked to sex hormone levels and only had a weak association with body fat. The lectin pathway contributed to fibrin clot lysis variability in KS, and levels of the fibrinogen-C3dg complex were similar in both KS and controls.
conclusionMen with KS demonstrate increased lectin complement pathway activation capacity, and increased MAP-1 and MASP1-201 expression. Altered immune function could be a specific characteristic of KS contributing to the comorbidity burden.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.